Acinic cell carcinoma medical therapy

Jump to: navigation, search

Acinic cell carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acinic cell carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Surgery

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Acinic cell carcinoma medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acinic cell carcinoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acinic cell carcinoma medical therapy

CDC on Acinic cell carcinoma medical therapy

Acinic cell carcinoma medical therapy in the news

Blogs on Acinic cell carcinoma medical therapy

Directions to Hospitals Treating Acinic cell carcinoma

Risk calculators and risk factors for Acinic cell carcinoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]

Overview

Low grade, low stage (I and II) and adequately resected acinic cell carcinoma are not considered for any further therapy, as their prognosis is excellent with surgery alone. Criteria for additional radiotherapy of acinic cell carcinoma does not differ with other salivary gland carcinomas. There is insufficient information regarding chemotherapy in acinic cell carcinoma. Observation of distant metastasis with a rate of 1 in 5 indicate the need for developing such regimen.

Medical Therapy

  • Low grade, low stage (I and II) and adequately resected acinic cell carcinoma are not considered for any further therapy, as their prognosis is excellent with surgery alone. additional medical therapies are:[1]

Radiotherapy

Criteria for additional radiotherapy of acinic cell carcinoma does not differ with other salivary gland carcinomas and include:[2]

Conversely Biron et al suggest that 'radiotherapy probably is not effective in acinic cell carcinoma.[3]

Chemotherapy

  • There is insufficient information regarding chemotherapy in acinic cell carcinoma.[4]
  • Some have suggested of positive effects of mTOR inhibitors due to acinic cell carcinoma, but no specific chemotherapy regimen have been currently approved.
  • Observation of distant metastasis with a rate of 1 in 5 indicate the need for developing such regimen.

References

  1. Vander Poorten, Vincent L. M.; Marchal, Francis; Nuyts, Sandra; Clement, Paul M. J. (2010). "Parotid carcinoma: Current diagnostic workup and treatment". Indian Journal of Surgical Oncology. 1 (2): 96–111. doi:10.1007/s13193-010-0022-x. ISSN 0975-7651.
  2. Patel, Neal R.; Sanghvi, Saurin; Khan, Mohemmed N.; Husain, Qasim; Baredes, Soly; Eloy, Jean Anderson (2013). "Demographic trends and disease‐specific survival in salivary acinic cell carcinoma: An analysis of 1129 cases". The Laryngoscope. 124 (1): 172–178. doi:10.1002/lary.24231. ISSN 0023-852X.
  3. Biron, Vincent L.; Lentsch, Eric J.; Gerry, Daniel R.; Bewley, Arnaud F. (2015). "Factors influencing survival in acinic cell carcinoma: A retrospective survival analysis of 2061 patients". Head & Neck. 37 (6): 870–877. doi:10.1002/hed.23686. ISSN 1043-3074.
  4. Vander Poorten, V.; Triantafyllou, A.; Thompson, L. D. R.; Bishop, J.; Hauben, E.; Hunt, J.; Skalova, A.; Stenman, G.; Takes, R. P.; Gnepp, D. R.; Hellquist, H.; Wenig, B.; Bell, D.; Rinaldo, A.; Ferlito, A. (2015). "Salivary acinic cell carcinoma: reappraisal and update". European Archives of Oto-Rhino-Laryngology. 273 (11): 3511–3531. doi:10.1007/s00405-015-3855-7. ISSN 0937-4477.

Linked-in.jpg